Cargando…

Among patients with advanced ovarian carcinoma, who benefits from bevacizumab the most?

Detalles Bibliográficos
Autores principales:	Babaier, Abdulaziz, Ghatage, Prafull
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477662/ https://www.ncbi.nlm.nih.gov/pubmed/37675330 http://dx.doi.org/10.21037/atm-23-903

Ejemplares similares

Mucinous Cancer of the Ovary: Overview and Current Status
por: Babaier, Abdulaziz, et al.
Publicado: (2020)

Low-Grade Serous Carcinoma of the Ovary: The Current Status
por: Babaier, Abdulaziz, et al.
Publicado: (2022)

Bevacizumab as adjunct to chemotherapy for chemoresistant ovarian cancer
por: Hamilton, Gerhard
Publicado: (2020)

Past, Present, and Future of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer
por: Mishra, Mona, et al.
Publicado: (2021)

Progression after discontinuation of bevacizumab in the first-line treatment of ovarian cancer
por: Nakai, Hidekatsu, et al.
Publicado: (2023)

Who benefits most from early salvage radiation therapy after prostatectomy?
por: Nath, Sameer K., et al.
Publicado: (2018)

Bevacizumab combined with chemotherapy in platinum-resistant ovarian cancer: beyond the AURELIA trial
por: Lyon, Kristopher A., et al.
Publicado: (2020)

Delving Into the Functional Meaning of Phenotypic Variation in Mycobacterial Persistence: Who Benefits the Most From Programmed Death of Individual Cells?
por: Burgess Tornaletti, Laura, et al.
Publicado: (2020)

Who benefits most?
por: Van Diermen, L.
Publicado: (2021)

Adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma
por: Kudo, Masatoshi
Publicado: (2023)

REBECA trial: a new piece of the evidence for bevacizumab in platinum-resistant recurrent ovarian cancer
por: Lavacchi, Daniele, et al.
Publicado: (2020)

Association of Hormone Receptor Expression with Survival in Ovarian Endometrioid Carcinoma: Biological Validation and Clinical Implications
por: Rambau, Peter, et al.
Publicado: (2017)

New machine learning model predicts who may benefit most from COVID-19 vaccination
por: Wedlund, Leia, et al.
Publicado: (2021)

Advancing Control of Cholera in the Interest of the Most Vulnerable in our Global Society
por: Ivers, Louise C
Publicado: (2018)

Etiology, Clinical Features, and Diagnosis of Vulvar Lichen Sclerosus: A Scoping Review
por: Singh, Nilanchali, et al.
Publicado: (2020)

The addition of bevacizumab to standard chemotherapy in breast cancer: which patient benefits the most?
por: Kruse, Vibeke, et al.
Publicado: (2013)

Who benefits from putting family life into ice?
por: Hovatta, Outi
Publicado: (2016)

Percutaneous dilatational tracheostomy: mostly safe, but do benefits outweigh risks?
por: Scales, Damon C, et al.
Publicado: (2014)

Another debriefing course! Who benefits?
por: Krogh, Kristian, et al.
Publicado: (2018)

Identifying high-risk stage IIIA cutaneous melanoma patients who might benefit from adjuvant therapy: the importance of micrometastatic tumor burden
por: Egger, Michael E.
Publicado: (2023)

Fit Older Adults with Advanced Myelodysplastic Syndromes: Who is Most Likely to Benefit from Transplant?
por: Abel, Gregory A., et al.
Publicado: (2020)

Atezolizumab plus bevacizumab and tremelimumab plus durvalumab: how should we choose these two immunotherapy regimens for advanced hepatocellular carcinoma?
por: Hatanaka, Takeshi, et al.
Publicado: (2022)

Treatment Options in Vulvar Lichen Sclerosus: A Scoping Review
por: Singh, Nilanchali, et al.
Publicado: (2021)

Bevacizumab in Advanced Cervical Cancer: Issues and Challenges for Low- and Middle-Income Countries
por: Gyawali, Bishal, et al.
Publicado: (2016)

Who benefits most from Lyon’s bike sharing system?
por: Cambe, Jordan, et al.
Publicado: (2020)

Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer
por: Pujade-Lauraine, Eric
Publicado: (2013)

The twin questions of personalized medicine: who are you and whom do you most resemble?
por: Kohane, Isaac S
Publicado: (2009)

Identifying patients who may benefit from treatment
por: Abacı, Adnan
Publicado: (2018)

COVID‐19 infection in primary central nervous system lymphoma treatment: Who is most at risk?
por: Lim, Sean H.
Publicado: (2022)

Accelerated partial breast irradiation: technically feasible but who will benefit?
por: Ross, Gillian
Publicado: (2005)

Current status of bevacizumab in advanced ovarian cancer
por: Tomao, Federica, et al.
Publicado: (2013)

Prospects for the future of epidermal growth factor receptor-tyrosine kinase inhibitors in combination with bevacizumab
por: Chikaishi, Yasuhiro, et al.
Publicado: (2020)

A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers
por: Tinker, Anna V., et al.
Publicado: (2022)

Cannabis use in gynecologic cancer patients in a Canadian cancer center
por: Black, Kristin A., et al.
Publicado: (2023)

Sexual Dysfunction in Cervical Cancer Survivors: A Scoping Review
por: Mishra, Neha, et al.
Publicado: (2021)

Management of Gynecologic Cancer During COVID-19 Pandemic: South Asian Perspective
por: Singh, Nilanchali, et al.
Publicado: (2022)

Ovarian transposition in rectal cancer: uncertain benefit at a high price
por: Fish, Rebecca
Publicado: (2022)

Maveropepimut-S, a DPX-Based Immune-Educating Therapy, Shows Promising and Durable Clinical Benefit in Patients with Recurrent Ovarian Cancer, a Phase II Trial
por: Dorigo, Oliver, et al.
Publicado: (2023)

Who benefits most from influenza vaccination policy: a study among the elderly in Beijing, China
por: Li, Tongtong, et al.
Publicado: (2016)

Who benefits most from studying abroad? A conceptual and empirical overview
por: Netz, Nicolai
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a8l5mda48mg1b16nnct2rdgifr